Drugs / Islets of Langerhans
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00579371 | Mar 2004 → Mar 2011 | type 1 diabetes mellitus | University of Nebraska | Terminated | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00679042 | Sep 2007 → Jul 2017 overdue | type 1 diabetes mellitus | CellTrans Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Islets of Langerhans | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00679042 ↗ |
| Known as | Islets of Langerhan (Islets) | “Islets of Langerhan (Islets)” NCT00679042 ↗ |
| Modality | Cell therapy | “Subjects will receive islets isolated from one donor pancreas per transplantation event.” NCT00579371 ↗ |
| Route | Other | “Islets will be infused intraportally.” NCT00579371 ↗ |